期刊文献+

死亡相关蛋白激酶在甲状腺乳头状癌中的表达及其意义 被引量:1

The expression of death-associated protein kinase in papillary thyroid carcinoma
原文传递
导出
摘要 目的观察死亡相关蛋白激酶(DAPK)在甲状腺乳头状癌(PTC)中的表达,探讨DAPK在甲状腺乳头状癌发生发展中的作用。方法采用免疫组织化学SP法和Westernblot免疫印迹法检测甲状腺乳头状癌42例、癌旁组织42例(正常甲状腺组织21例和结节性甲状腺肿21例)。免疫组织化学SP法检测蛋白表达位置,Western检测蛋白表达的差异。结果免疫组织化学结果显示DAPK基因表达于细胞质及胞膜,癌旁组织中表达率73.81%(31/42)高于癌组织40.48%(17/42)。Western结果显示甲状腺乳头状癌组织中DAPK阳性表达率为35.71%(15/42),癌旁组织中为66.67%(28/42),癌旁组织的表达显著高于癌组织(χ2=8.052,P〈0.01)。淋巴结癌转移阳性的癌组织DAPK阳性表达率17.65%(3/17)低于淋巴结转移阴性的病例48.00%(12/25),(χ2=4.061,P〈0.05)。DAPK的表达与患者的年龄、性别、肿瘤大小情况无明显相关(P〉0.05)。结论DAPK参与细胞凋亡,其低表达或不表达可能参与了甲状腺乳头状癌的发生发展过程。 Objective To observe the expression of death-associated protein kinase (DAPK) in papillary thyroid carcinoma (PTC) , and explore the role of DAPK in the occurrence and development of PTC. Methods The expression of DAPK was detected by SP immunohistochemical technique and Western blotting in 42 cases of PTC tissues, 42 cases of para-PTC tissues (21 cases of normal thyroid tissues and 21 cases of nodular goiter tissues). The location of DAPK protein expression was examined by SP immunohistochemical technique, and that the differential expression of DAPK protein by Westem blotting, respectively. Results By SP immunohistochemical technique, DAPK gene was expressed in the cytoplasm and membrane, and the positive rate of DAPK in para-PTC was 73.81% (31/42), higher than 40.48% (17/42) in PTC. By Western blotting, the positive rate of DAPK in PTC and para-PTC tissues was 35.71% and 66.67% respectively. The positive rate of DAPK in benign thyroid issues was obviously higher than that in tumor tissues (X2 = 8. 052, P 〈 0.01 ). The positive rate of DAPK expression in the patients with lymph node involvement was 17.65% (3/17), lower than in those without lymph node involvement [48.00% (12/25) ] , (χ2 = 4. 061,P 〈 0.05 ). The expression of DAPK was not associated with the age, sex, or tumor size of the patients obviously ( P 〉 0.05 ). Conclusion DAPK is involved in cell apoptosis, and its low or even no expression may be involved in the oncogenesis of PTC.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2010年第3期342-344,共3页 Chinese Journal of Experimental Surgery
关键词 甲状腺癌 死亡相关蛋白激酶 脱噬作用 Thyroid carcinoma Death-associated protein kinase Apoptosis
  • 相关文献

参考文献10

  • 1卢秀波,王利,王家祥,娄卫华,余捷凯,郑树.血清蛋白质指纹图谱在甲状腺癌诊断中的应用[J].中华实验外科杂志,2006,23(6):703-705. 被引量:16
  • 2Feinstein E,Druck T,gastury K,et al.Assignment of DAP1 and DAPK-Genes that positively mediate programmed cell death triggered by IFN-γ-to chromosome regions 5p12.2 and 9q34.1,respectively.Genomics,1995,29:305-307.
  • 3Jin YJ,Blue EK,Gallagher PJ.Control ofdeath-associated protein kinsse(DAPK)activity by phosphorylation and proteasomal degradation.J BiolChem,2006,281:39033-39040.
  • 4Shang T,Joseph J,Hillard CJ,et al.Death-associated protein kinese as a sensor of mitochondrial membrane potentia:l role of lysosome inmitochondrial toxin-induced cell death.J BiolChem,2005,280:34644-34653.
  • 5Kogel D,Reimertz C,Dubm H,et al.The death associated protein(DAP)kinase homologue D1 k/ZIP kinase induces p19ARF and p53-independent apoptosis.Eur J Cancer,2003,39:249-256.
  • 6胡礼炳,王国民,张利能,查锡良.膀胱癌细胞中DAPK基因启动子甲基化状态分析[J].中华实验外科杂志,2007,24(4):489-491. 被引量:13
  • 7Hu S,Liu D,Tufano RP,et al.Association of aberrant methylation of tumor suppressorgenes with tumnor aggressiveness and BRAF mutation in papillary thyroid cancer.Int J Cancer,2006,119:2322-2329.
  • 8Yamanaka M,Watanabe M,Yamada Y,et al.Altered mathylation of multiple genes in carcino-genesis of the prostate.Int J CAtncer,2003,106:382-387.
  • 9Bialik S,KimehiA.DAP-kinase as a target fordrug design in cancerand diseases associated with accelerated cell death.Semin Cancer Biol,2004,14:283-294.
  • 10张东伟,杨维良.甲状腺癌基因治疗的现状及展望[J].中华实验外科杂志,2005,22(2):255-256. 被引量:16

二级参考文献29

  • 1吕新生.提高甲状腺癌患者的治疗效果及生活质量[J].中国普外基础与临床杂志,2004,11(6):481-482. 被引量:7
  • 2乔忠杰,王国民,刘银坤.高复发性膀胱移行细胞癌基因组非平衡性的变化[J].中华实验外科杂志,2005,22(7):871-872. 被引量:5
  • 3Drosten M,Stiewe T,Putzer BM.Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.Hum Gene Ther,2003,14:971-982.
  • 4Takeda T,Inaba H,Yamazaki M,et al.Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.The journal of Clinical Endocrinology & Metabolism,2003,88:3531-3538.
  • 5Zhang R,DeGroot LJ.An adenoviral vector expressing functional heterogeneous proteins,herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.Endocr Relat Cancer,2001,8:315-325.
  • 6Zhang R,DeGroot LJ.Gene therapy of a rat follicucular thyroid carcinoma model with adenviral vectors transducing murinernter leukin-12.Endocrinology,2003,144:1393-1398.
  • 7Nagayama Y,Yokoi H,Takeda K,et al.Adenovirus-Mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.J Clin Endocrinol Metab,2000,85:4081-4086.
  • 8Ye C,Feng C,Wang S,et al.sFlt-1 gene therapy of follicular thyroid carcinoma.Endocrinology,2004,145:817-822.
  • 9Patel A,Jhiang S,Dogra S,et al.Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.Pediatr Res,2002,52:737-744.
  • 10Kitazono M,Robery R,Zhan Z,et al.Low concentrations of the histone deacetylase inhibitor,depsipeptide(FR901228),increase expression of the Na(+)/I(-) symptorter and iodide accumulation in poorly differentiated thyroid carcinoma cells.J Clin Endocrinol Metab,2001,86:3430-3435.?A

共引文献41

同被引文献11

  • 1卢秀波,安兆峰,王庆兆,殷德涛,邱新光.Survivin和c-myc在分化型甲状腺癌中的表达及临床意义[J].中华实验外科杂志,2004,21(6):705-706. 被引量:18
  • 2嵇庆海,王玉龙,郭智.甲状腺癌诊治进展[J].肿瘤研究与临床,2006,18(3):214-216. 被引量:27
  • 3Shattuck TM,Westra WH,Ladenson PW,et al.Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma.N EngJ Med,2005,352:2406-2412.
  • 4Sonobe S,Miyamoto H,Nobukawa B,et al.Prognostic value of CD44 isoform expression in thymic epithelial neoplasms.Cancer,2005,103:2015-2022.
  • 5Chuang CK,Liao SK.Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas.Anticancer Res,2003,23:4635-4639.
  • 6Hoshimoto K,Yamauchi N,Takazawa Y,et al.CD44 variant 6 in endometrioid carcinoma of the uterus:its expression in the adenocarcinoma component is an independent prognostic marker.Pathol Res Pract,2003,199:71-77.
  • 7Shariat SF,Lotan Y,Saboorian H,et al.Survivin expression in associated with feartures of biologically aggressive prostate carcinoma.Cancer,2004,10:751-757.
  • 8Delellis RA,Lioyd RV,Heitz PU,et al.Pathology and genetics of tumors of the endocrine organs.3rd ed.Lyon:IARC Press,2004.
  • 9Santoro M,Melillo RM,Fusco A.RET/PTC activation in papillary thyroid carcinoma:European Journal of Endocorinology Prize Lecture.EurJ Endocrinol,2006,155:645-653.
  • 10林益凯(综述),赵文和(审校).甲状腺乳头状癌多发病灶的克隆起源研究进展[J].国际肿瘤学杂志,2007,34(9):668-670. 被引量:5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部